EAH ECO Animal Health Group plc
ECO Animal Health Group plc, together with its subsidiaries, manufactured and supply animal health products internationally. The company provides Aivlosin, a macrolide antibiotic for the treatment of enteric and respiratory diseases in pigs and poultry. It also offers Ecomectin to treat parasites in cattle, sheep, and pigs; and ECOVAXXIN MS, a mycoplasma solution. ECO Animal Health Group plc was founded in 1972 and is based in London, the United Kingdom.…
Industry Peers
Drug Manufacturers - Specialty & GenericKey Statistics
About ECO Animal Health Group (LON: EAH)
›
ECO Animal Health Group (LON: EAH) is listed on the London Stock Exchange, where its shares trade in pence sterling (GBp). It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 213 employees.
The shares were at 83.00 GBp on 19 November 2026, up 5.7% over 52 weeks.
At a market capitalisation of 55.38M GBP, it trades at 27.7 times trailing earnings and 16.7 times forward earnings. The median trailing P/E of its 17 largest Drug Manufacturers - Specialty & Generic peers is 24.7, a premium of 12% for EAH.
ECO Animal Health Group reports return on equity of 2.5%, an operating margin of 6.5% and revenue up 3.7% year over year.
It holds more cash than debt, a net cash position of 20.50M GBP. Its Piotroski F-score is 8 out of 9, a strong reading of its financial health. 5 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 197.80 GBp is 138.3% above the current price.